Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of Human BCMA Targeted T Cells Injection for the
treatment of BCMA-positive relapsed/refractory multiple myeloma. Patients will be given a
conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single
infusion of BCMA CAR+ T cells.
Phase:
Phase 1
Details
Lead Sponsor:
Hrain Biotechnology Co., Ltd.
Collaborators:
First Affiliated Hospital of Wenzhou Medical University Shanghai Changzheng Hospital The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine